You’re using a public version of DrugPatentWatch with 5 free searches available | Register to unlock more free searches. CREATE FREE ACCOUNT

Last Updated: April 26, 2024

Claims for Patent: 10,143,749

✉ Email this page to a colleague

« Back to Dashboard

Summary for Patent: 10,143,749

Title:	Bispecific anti-Cmet/anti-Her2 antibodies
Abstract:	There are provided an anti-c-Met/anti-Her2 bispecific antibody, and a method for preventing and/or treating cancer using the same.
Inventor(s):	Cho; Mi Young (Seoul, KR), Lin; Powei (Hwaseong-si, KR), Lee; Seung Hyun (Suwon-si, KR), Cheong; Kwang Ho (Seoul, KR), Koh; Young Jun (Yongin-si, KR), Yi; Christina (Seongnam-si, KR), Hwang; Jae Woong (Seoul, KR)
Assignee:	SAMSUNG ELECTRONICS CO., LTD. (Suwon-si, KR)
Application Number:	14/229,308
Patent Claims:	1. An anti-c-Met/anti-Her2 bispecific antibody comprising (a) an anti-c-Met antibody in an IgG form comprising six complementarity determining regions (CDRs), linked to (b) an antigen-binding fragment of an anti-Her2 antibody comprising six complementarity determining regions, wherein the anti-c-Met antibody comprises: (i) a heavy chain variable region comprising a CDR-H1 comprising the amino acid sequence of SEQ ID NO: 1; a CDR-H2 comprising the amino acid sequence of SEQ ID NO: 2 and a CDR-H3 comprising the amino acid sequence of SEQ ID NO: 3; and (ii) a light chain variable region comprising a CDR-L1 comprising the amino acid sequence of SEQ ID NO: 10; a CDR-L2 comprising the amino acid sequence of SEQ ID NO: 11; and a CDR-L3 comprising the amino acid sequence of SEQ ID NO: 13, SEQ ID NO: 14, SEQ ID NO: 15, or SEQ ID NO: 16. 2. The anti-c-Met/anti-Her2 bispecific antibody according to claim 1, wherein the antigen-binding fragment is an scFv, (scFv)2, Fab, Fab' or F(ab').sub.2. 3. The anti-c-Met/anti-Her2 bispecific antibody according to claim 1, wherein the anti-c-Met antibody comprises: (i) a heavy chain variable region comprising the amino acid sequence of SEQ ID NO: 17, and (ii) a light chain variable region comprising the amino acid sequence of SEQ ID NO: 114, SEQ ID NO: 18, SEQ ID NO: 19, SEQ ID NO: 20, or SEQ ID NO: 21. 4. The anti-c-Met/anti-Her2 bispecific antibody according to claim 1, wherein the anti-c-Met antibody comprises: (i) a heavy chain comprising the amino acid sequence of SEQ ID NO: 62, the amino acid sequence from positions 18 to 462 of SEQ ID NO: 62, the amino acid sequence of SEQ ID NO: 64, the amino acid sequence from positions 18 to 461 of SEQ ID NO: 64, the amino acid sequence of SEQ ID NO: 66, or the amino acid sequence from positions 18 to 460 of SEQ ID NO: 66; and (ii) a light chain comprising the amino acid sequence of SEQ ID NO: 68, the amino acid sequence from positions 21 to 240 of SEQ ID NO: 68, the amino acid sequence of SEQ ID NO: 70, the amino acid sequence from positions 21 to 240 of SEQ ID NO: 70. 5. The anti-c-Met/anti-Her2 bispecific antibody according to claim 1, wherein the anti-c-Met antibody comprises a heavy chain comprising the amino acid sequence of SEQ ID NO: 66 or the amino acid sequence from positions 18 to 460 of SEQ ID NO: 66, and a light chain comprising the amino acid sequence of SEQ ID NO: 68 or the amino acid sequence from positions 21 to 240 of SEQ ID NO: 68. 6. The anti-c-Met/anti-Her2 bispecific antibody according to claim 1, wherein the anti-Her2 antigen binding fragment is an antigen binding fragment from Trastuzumab or Pertuzumab. 7. The anti-c-Met/anti-Her2 bispecific antibody according to claim 1, wherein the antigen-binding fragment of the anti-Her2 antibody is covalently linked to the C-terminus of the anti-c-Met antibody. 8. The anti-c-Met/anti-Her2 bispecific antibody according to claim 7, wherein the antigen-binding fragment of the anti-Her2 antibody comprises a heavy chain variable region comprising the sequence of SEQ ID NO: 109 and a light chain variable region comprising the sequence of SEQ ID NO: 111. 9. A pharmaceutical composition comprising the anti-c-Met/anti-Her2 bispecific antibody according to claim 1 and a pharmaceutically acceptable carrier. 10. A method of treatment of a cancer, comprising administering the anti-c-Met/anti-Her2 bispecific antibody of claim 1 to a patient in need thereof.

Details for Patent 10,143,749

Subscribe to access the full database, or Try a Trial
Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Genentech, Inc.	HERCEPTIN	trastuzumab	For Injection	103792	09/25/1998	⤷ Try a Trial	2033-03-28
Genentech, Inc.	HERCEPTIN	trastuzumab	For Injection	103792	02/10/2017	⤷ Try a Trial	2033-03-28
Genentech, Inc.	PERJETA	pertuzumab	Injection	125409	06/08/2012	⤷ Try a Trial	2033-03-28
Genentech, Inc.	HERCEPTIN HYLECTA	trastuzumab and hyaluronidase-oysk	Injection	761106	02/28/2019	⤷ Try a Trial	2033-03-28
>Applicant	>Tradename	>Biologic Ingredient	>Dosage Form	>BLA	>Approval Date	>Patent No.	>Expiredate

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.